Oncofertility: a grand collaboration between reproductive medicine and oncology

Teresa K Woodruff

The Thomas J Watkins Professor of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, 303 E Superior Street, Lurie 10-250, Chicago, Illinois 60611, USA

Correspondence should be addressed to T K Woodruff; Email: tkw@northwestern.edu

Abstract

In 2007, I was asked by the University of Calgary to participate in a symposium called ‘Pushing the Boundaries – Advances that Will Change the World in 20 Years’. My topic was oncofertility, a word I had just coined to describe the intersection of two disciplines – oncology and fertility – and I was thrilled to share my passion for this new field and help young women with cancer protect their future reproductive health. Fertility preservation in the cancer setting lacked a concerted effort to bridge the disciplines in an organized manner. In early 2015, I was delighted to deliver a presentation for the Society for Reproduction and Fertility titled ‘Sex in Three Cities’, where I gave an update on the oncofertility movement, a remarkable cross-disciplinary, global collaboration created to address the fertility preservation needs of young cancer patients. During my tour of the UK, I was impressed by the interest among the society and its members to engage colleagues outside the discipline as well as the public in a dialogue about cutting-edge reproductive science. In this invited review, I will describe the work of the Oncofertility Consortium to provide fertility preservation options in the cancer setting and accelerate the acceptance of this critical topic on a global scale. I hope that one day this word and field it created will change the world for women who had been left out of the equation for far too long.

Introduction

Young cancer patients, facing the devastating news that their early careers, college plans, or childhood playtime will be forever changed by the fight against a ruthless disease, are often unaware that the life-preserving treatments they will undergo can also threaten their future fertility (Lobo 2005, Meirow et al. 2005, Jeruss & Woodruff 2009, Barrett et al. 2010, De Vos et al. 2014, Wallace et al. 2014). Additionally, the potential loss of endocrine support of hormonally responsive tissues can trigger a cascade of long-term medical and quality-of-life problems. Beyond cancer, several non-malignant diseases and conditions, as well as their treatments, can also negatively affect reproductive function (Hirshfield-Cytron et al. 2011).

Ideally, the impact of a disease or its treatment on future fertility and endocrine health should be addressed as part of the initial comprehensive care plan for young patients, but the decision to protect fertility from the damaging effects of treatments, like radiation and chemotherapy, is complicated by the patients’ age, marital status, whether they can delay treatment, and sometimes, the uncertainty of survival. The juxtaposition of a cancer diagnosis and the risk of future infertility in young adults and children can be overwhelming for individual patients and their parents and partners, and contemplating the impact of cancer treatment on fertility may be nearly impossible at a time when the focus is on survival. The conversation about reproductive health in young patients diagnosed with a fertility-threatening disease or treatment is particularly complex, covering topics from basic biology, medical practice planning, health access, and reproductive rights, to ethical, social, moral, cultural, religious, and personal perspectives. The conversation includes many stakeholders – practitioners, patients, parents, and partners, and even the public, policymakers, and advocates (Woodruff & Snyder 2007, Dolin et al. 2010, Woodruff et al. 2010, 2013, Gracia & Woodruff 2012).

A decade ago, fertility preservation in the cancer setting was not a new idea, but there was no coordinated effort to link cancer care and fertility management – even existing centers of excellence may have had only a single practitioner who managed care in an ad hoc manner. To better meet the fertility and endocrine health needs of young women and girls facing any fertility-threatening condition or treatment, the Oncofertility Consortium was created in 2005 (http://oncofertility.northwestern.edu; Woodruff 2010; Table 1). The initiative began in North America, but there are many more programs developing around the globe (Ataman et al. 2015).
Table 1 List of valuable oncofertility online resources with URLs.

<table>
<thead>
<tr>
<th>Oncofertility online resources</th>
<th>Website links</th>
</tr>
</thead>
<tbody>
<tr>
<td>OC-SHAREs: OC has created several resources, available through the OC-Scientific Help Agreement for Research Endeavors or OC-SHAREs program, to help the scientific community carry out basic research in support of this mission</td>
<td><a href="http://oncofertility.northwestern.edu/oncofertility-consortium-scientific-help-agreement-research-endeavors-shares-program">http://oncofertility.northwestern.edu/oncofertility-consortium-scientific-help-agreement-research-endeavors-shares-program</a></td>
</tr>
<tr>
<td>Global Oncofertility Partners: Global Partners of the Oncofertility Consortium receive tools and guidance to set up their own consortium. We serve global partners in an effort to build and expand their existing services and outreach</td>
<td><a href="http://oncofertility.northwestern.edu/global-oncofertility-partners">http://oncofertility.northwestern.edu/global-oncofertility-partners</a></td>
</tr>
<tr>
<td>Oncofertility Decision Tool Web Portal: the Web Portal hosts decision tools designed to help health care providers navigate fertility preservation options discussions with their patients, including clinical guidelines and patient education materials</td>
<td><a href="http://oncofertility.northwestern.edu/ODT-web-portal">http://oncofertility.northwestern.edu/ODT-web-portal</a></td>
</tr>
<tr>
<td>MyOncofertility: MyOncofertility.org is an interactive patient education resource geared toward the adolescent population that provides authoritative information to patients, parents, and partners whose fertility may be impaired by lifesaving cancer treatment</td>
<td><a href="http://www.myoncofertility.org/">http://www.myoncofertility.org/</a></td>
</tr>
<tr>
<td>SaveMyFertility: SaveMyFertility.org is an authoritative resource for adult cancer patients and the parents of children with cancer who want to learn more about preserving their fertility before and during cancer treatment and protecting their hormonal health after treatment</td>
<td><a href="http://www.savemyfertility.org/">http://www.savemyfertility.org/</a></td>
</tr>
<tr>
<td>National Physicians Cooperative: the National Physicians Cooperative (NPC) provides access to human ovarian tissue and a collaborative forum for the exchange of ideas, clinical research methods, and technologies to drive breakthroughs in basic reproductive physiology that will be translated directly to clinical medicine</td>
<td><a href="http://oncofertility.northwestern.edu/physicians/about-the-national-physicians-coopnpc">http://oncofertility.northwestern.edu/physicians/about-the-national-physicians-coopnpc</a></td>
</tr>
<tr>
<td>Patient Navigator Site: treatment for certain diseases like cancer may affect your fertility. This means that it may not be possible for you to have a child naturally. You can learn more about your options for family building and watch and listen to patient stories on this website</td>
<td><a href="http://preservefertility.northwestern.edu/">http://preservefertility.northwestern.edu/</a></td>
</tr>
<tr>
<td>Oncofertility Blog: a collection of newsworthy items and discussions about important oncofertility issues</td>
<td><a href="http://blog.oncofertility.northwestern.edu/">http://blog.oncofertility.northwestern.edu/</a></td>
</tr>
</tbody>
</table>

Moreover, there are a number of guidelines that have been issued from societies around the globe that provide guidance to clinicians regarding fertility preservation and restoration (http://oncofertility.northwestern.edu/ODT-web-portal#guidelines). In this review, I would like to take you through the first decade of the Oncofertility Consortium – where we were when it started and where we stand today.

**Scope of the problem**

Advances in cancer diagnosis and the introduction of new cancer treatments have dramatically improved the odds of survival, permitting patients and practitioners to think well beyond the cure to future quality of life. Unfortunately, these life-saving treatments can also have a profoundly negative impact on reproductive endocrine function and fertility. In 2006, it was estimated that nearly 750,000 young women in the USA had their childbearing years interrupted to undergo cancer treatment. Among these female cancer survivors who were under the age of 40 at diagnosis, the chance of achieving pregnancy was 20% lower in those diagnosed as children and 50% lower in those diagnosed as young adults compared to female siblings without cancer (Green et al. 2009a). When extrapolated globally, this level of infertility and its consequences on survivors’ quality of life represent an enormous unmet need.

Although cancer is often thought of as a disease of aging, the number of young patients whose reproductive futures may be affected by cancer treatment is not small. In the USA in 2014, more than 1.6 million patients received a cancer diagnosis (National Cancer Institute & Surveillance Epidemiology and End Results Program 2014a) and ~14 million were diagnosed worldwide (World Health Organisation 2015). In the USA, ~23% of new cancer diagnoses in 2007–2011 were made in patients younger than 45 years of age (National Cancer Institute & Surveillance Epidemiology and End Results Program 2014a), a time when many may be contemplating or actively building their families. It is these patients for whom a reproductive consult should be considered at the time of diagnosis to address options for preserving fertility – before cancer treatment begins (Lobo 2005, Meir et al. 2005, Jeruss & Woodruff 2009, Woodruff 2010, De Vos et al. 2014, Wallace et al. 2014).

Children with cancer represent a special population of individuals for whom the cancer survival statistics have been most impressive – ~85% of prepubertal cancer patients (age 0–14 years) are likely to survive their disease (National Cancer Institute & Surveillance Epidemiology and End Results Program 2014b, Smith et al. 2014). For this reason, addressing the late effects associated with cancer treatment, such as cardiac dysfunction, neurocognitive impairment, and reproductive and endocrine issues, has taken on a new urgency. Cancer treatments may also cause many young patients
to experience difficulty transitioning through puberty, with loss of bone and muscle development and delayed development of secondary sex characteristics. Understanding the potential effects of cancer treatment on both short- and long-term reproductive and endocrine health, and how to mitigate these risks before treatment begins, presented a daunting challenge.

Minding the gaps

Back in 2005, when oncofertility programs were just starting, men and pubertal boys were regularly offered sperm banking as an option to preserve their fertility prior to cancer treatment. Yet young women who had the same hope for survival had few to no fertility preservation options made available to them. There were three main gaps that created this chasm in care – an information gap, a data gap, and an option gap (Woodruff 2010). With regard to the information gap, there was limited dialogue between oncology and fertility specialists about the fertility concerns of young cancer patients (Kohler et al. 2011). There was also a general reluctance among oncologists to discuss reproductive issues with young patients and their parents (Quinn et al. 2012). They would talk about how patients might lose their hair follicles because of their cancer treatment but were not comfortable talking about how patients might lose their ovarian follicles.

A cancer diagnosis in a young person seems particularly cruel and is understandably accompanied by an urgency to begin treatment. As such, many practitioners may assume that parents are solely interested in the survival of their child, not the some far-off future risk to fertility or endocrine health. Yet our early assessment of the attitudes of adult survivors of childhood cancer told a very different story – young women and their parents alike wished that they had fertility preservation options made available to them before they started treatment (Nieman et al. 2006, 2007, Gorman et al. 2012). For many of these adult survivors, their cancer treatment had become a distant memory, but the issue of infertility remained as a real and present problem that limited their social life and curtailed their hopes of a biologic family.

The data gap further hindered the discussion – both between oncologists and fertility specialists and between oncologists, patients, and parents – since little was known about the fertility effects of specific cancer treatments. It was, and continues to be, very difficult to be precise about the risks posed by specific cancer treatments on fertility and reproductive function. Several studies have demonstrated that cancer therapies destroy ovarian follicles and accelerate ovarian aging, influence puberty and menstruation, and shift the age of menopause earlier (Goodwin et al. 1999, Sklar et al. 2006, Gracia et al. 2012, Johnson et al. 2013). One study estimated that cancer treatment accelerated ovarian aging by 7 years, meaning that the ovaries of a 30-year-old cancer survivor would function like the ovaries of a 37-year-old (Levine et al. 2015). The best available evidence on the effect of cancer treatment comes from the Childhood Cancer Survivor Study (CCSS), a longitudinal cohort study of cancer survivors who were younger than 21 years of age at diagnosis compared to a sibling control group. In one analysis, female cancer survivors were more likely to have clinical infertility (>1 year of attempts to conceive) and the risk increased with exposure to increasing doses of radiation and chemotherapy with alkylating agents (Green et al. 2009a, 2011, Barton et al. 2013). Cancer survivors exposed to pelvic radiation or high-dose alkylating agents or procarbazine were also more likely to experience acute ovarian failure and premature menopause (Green et al. 2009b). Exposure to more than 7.5 Gy to the testes or treatment with high doses of alkylating agents, cyclophosphamide, or procarbazine was associated with lower fertility among men enrolled in the study (Green et al. 2010). The lack of information about the specific effects of certain cancer treatments and regimens on various markers of reproductive and endocrine function continues to be a major issue for the field, as long-term studies such as the CCSS are costly and difficult to manage.

The final issue was the option gap. Even though emergency IVF – performed in the window between cancer diagnosis and treatment – was available in 2005, it was rare that this option would be offered to young women with a newly diagnosed cancer, and there was no easy way to quickly navigate patients from oncology to fertility care and back again. Reproductive endocrinologists and fertility specialists were not accustomed to handling rapid consults for patients who required urgent care prior to undergoing cancer treatment. Moreover, because this intervention was not appropriate for all patients, oncologists were reluctant to engage in a dialogue about it, knowing some patients with aggressive disease or hormone-responsive disease would have no ability to alter the course of their treatment to undergo hormonal stimulation for IVF.

As we worked through these gaps, it also became clear that fertility concerns touch more than just those patients affected by cancer. For example, gastrointestinal diseases, rheumatologic disorders, non-malignant hematologic conditions (most prominently β-thalassemia), neurologic disorders, renal disorders, gynecologic conditions, and metabolic diseases can adversely impact the reproductive axis, yet there is little information about these effects or what fertility preservation options may be provided (Hirshfield-Cytron et al. 2011). Moreover, the negative iatrogenic effects of various treatments and procedures for non-malignant diseases on reproductive function are only now being appreciated. Just as for cancer patients, these diseases and treatments can lead to impaired gonadal function, endocrine function,
sexual function, or ability to carry a pregnancy to term. We know that cancer patients are interested in fertility interventions, but clinical practice is only now recognizing the need for education and advocacy for this broader group of patients. In response, our focus expanded to ensure that all patients facing a disease or treatment that limits reproductive function can benefit from the findings of basic and clinical reproductive research in fertility preservation and that breakthroughs made and technologies developed at the bench are translated to clinical practice rapidly and effectively.

**The Oncofertility Consortium**

When it was first established, the Oncofertility Consortium worked to address the first and last gaps – the information gap and the option gap – by educating providers and allied health professionals across disciplines about fertility preservation in the cancer setting. We facilitated cross-disciplinary cooperation between oncologists and reproductive endocrinologists, engaged the public and broadened the discussion about oncofertility, and accelerated the pace and quality of basic and clinical research to develop a larger range of fertility preservation options, including biological and non-biological options for males and females, pubertal and young adult patients (Woodruff 2010, Waimey et al. 2013). Some of these options remain experimental, while others are now standard of care for fertility preservation in the cancer setting.

The mission of the Oncofertility Consortium was to serve as an authoritative voice for cancer patients facing fertility-threatening treatments and to create new corridors of discovery and dialogue between research and clinical practice at the intersection of oncology, pediatrics, reproductive science, policy research, reproductive health law, bioethics, communication science, and cognitive and learning science (Woodruff & Snyder 2007, Woodruff 2010). On the scientific side, we wanted to address fundamental questions of ovarian follicle growth and maturation as well as discover how follicles could be preserved without appreciable damage for long-term storage. For children with cancer who cannot undergo emergency IVF to retrieve mature oocytes or produce embryos for cryopreservation, retrieving ovarian tissue and preserving the immature follicles is their only remaining option to preserve fertility. Figuring out how to cryopreserve these small follicles and then recover them at a later date to restore fertility and endocrine function required the scientific community to come together in new and innovative ways.

We also had an existing unmet clinical need. Approximately 130 000 women receive a cancer diagnosis in the USA each year (National Cancer Institute & Surveillance Epidemiology and End Results Program 2014a), and some sort of fertility consultation pathway that addressed the fertility threat, or lack of a threat, needed to be implemented. In cases in which intervention was also required, we needed plans for Institutional Review Board (IRB)-approved experimental options and new lines of communication between oncology and reproductive endocrinology. We needed legal, ethical, and insurance and reimbursement issues to be addressed (Campo-Engelstein 2010a,b, 2011, Dolin et al. 2010). These were complicated and interconnected issues, but we recognized that any discovery we made at the bench would not be translated into clinical care on the rapid time scale required or with the broad quality metrics across practices that would be in the best interest of patients. Finally, we needed to broadly educate pediatric and adult oncologists and reproductive endocrinologists and urologists to understand the nature of the fertility concerns of cancer patients and their parents and integrate a new patient category with unique care requirements into an already busy program (Jeruss & Woodruff 2009, Gardino et al. 2010, Redig et al. 2011, Gracia & Woodruff 2012). These complex decisions required the assembly of large teams, which could be unwieldy, but once assembled and functional, they could shift the burden from an individual to a broad team to achieve our goals.

Since its founding, the Oncofertility Consortium has pursued five solution-guided objectives (Waimey et al. 2013, Woodruff 2013). We developed and applied new biomaterials for the ex vivo and in vivo growth of ovarian follicles with the ultimate goal of providing new options for preserving both fertility and endocrine function in patients. We also designed and tested mitigation strategies to reduce the off-target effects of chemotherapy on oocyte function and thereby protect future endocrine function – we hope that 1 day these strategies will eliminate the need for oncofertility. We developed and tested physician- and patient-guided tools to increase the inclusion and adherence of patients at risk of negative iatrogenic reproductive effects in fertility preservation studies. We created and disseminated patient-, provider-, and public-facing didactics and, finally, formally supported the training of the next generation of leaders at the intersection of reproductive health and disease care. Even as we created our USA-based consortium of physicians and allied health professionals, basic and clinical researchers, patients, and advocates, we also reached out globally to increase the awareness of oncofertility and fertility preservation and to catalyze research and its translation to patient care through a shared vision, shared technology and resources, and a shared commitment to patients and the public. We understood that outstanding science and patient-facing activities happening around the world could be better harnessed if we all worked together and shared best practices to create comprehensive care plans. As a result, there are now centers in 19 countries actively engaged in the global oncofertility community.
Fertility preservation decision-making

Making decisions about preserving future endocrine function and fertility requires that patients weigh information from many different sources – their doctors, their families, society – at a highly emotional time, when they are facing an existential crisis about themselves, their survival, and their future (Clayman et al. 2007, Gardino et al. 2010, Woodruff et al. 2010, 2013, Gracia & Woodruff 2012, Murphy et al. 2012, Quinn et al. 2012, Quinn & Vadaparampil 2013, Duncan et al. 2014). As with any decision, patients need to be fully aware of and understand their options, but this can be particularly challenging for patients who have just received a cancer diagnosis and must make a decision within a tight time frame. Fertility interventions in the conventional infertility setting are not urgent and patients are often well aware of their fertility status and are some of the most well-educated consumers of health information. In contrast, the young cancer patient is not generally aware of their reproductive health or fertility concerns, so the discussion about fertility options requires a new kind of language to describe the potential impact of their treatment on endocrine and reproductive outcomes. Finally, there are issues of geographic access to care and financial constraints that feed into the decision-making process.

One of the ways we have found to significantly facilitate fertility preservation decision-making is through the use of a patient navigator (http://oncofertility.northwestern.edu/patient-navigators). The oncofertility patient navigator at Northwestern University is well-versed in the patient’s oncology diagnosis and treatment plan, as well as the fertility consequences of the planned treatment and the available fertility preservation options. The navigator can further the discussion and readily move the patient from oncology to reproductive endocrinology services and then back to cancer care as quickly as possible (Scott-Trainor 2010, Gracia & Woodruff 2012). The Oncofertility Consortium has also made available a decision tool web portal, where health care providers can find various decision tools and resources to help them work through the available fertility preservation options with their patients (http://oncofertility.northwestern.edu/ODT-web-portal#DecisionTools).

Another patient-targeted approach was the development of a network of providers so that patients are able to receive care closer to home (the Oncofertility Consortium National Physicians Cooperative (NPC), http://oncofertility.northwestern.edu/physicians/about-the-national-physicians-coop-npc; the Global Oncofertility Network, http://oncofertility.northwestern.edu/global-oncofertility-partners; and a growing Pediatric Oncofertility Network, http://oncofertility.northwestern.edu/pediatric- oncologists). This represented a radical shift, from only a few centers of excellence to more evenly distributed and standardized oncofertility care available across the country, and now globally. The NPC has grown to 59 clinical sites nationwide, including 20 pediatric clinical sites. The NPC shares its collective practice experience by providing the NPC users manual, IRB templates, and billing resources to practices considering the implementation of their own fertility preservation programs (Gracia & Woodruff 2012). The NPC also obtains donated human ovarian tissues and oocytes under IRB-approved protocols for basic investigation and distributes them across the network for research purposes. The activities of the NPC member sites have resulted in a substantial collection of rare research tissue, with more than 130 samples taken over the last 5 years, and the amount of research tissues collected has increased significantly in recent years.

Other tools to facilitate decision-making include a global fertility hotline with an oncofertility patient navigator available to physicians and patients (http://oncofertility.northwestern.edu/fertline; 866-708-FERT); a patient-facing website called Myoncofertility.org that provides information to patients, parents, and partners about fertility issues and what can be done to preserve fertility at various points from diagnosis to treatment; a SaveMyFertility module (including a microsite, fact sheets, pocket guides, and mobile app) for providers; and a list of ‘cancer friendly’ adoption agencies. All of these patient educational tools are free and available for download and can be customized. The Oncofertility Consortium name and associated awareness ribbon are used together with the home institution’s name to highlight the concerted global effort that is in place to address patient issues. Our goal is to provide authoritative, up-to-date, enduring educational materials that can be accessed anywhere, at any time, and in any language.

One of the most important things that has happened since the formation of the Oncofertility Consortium is the development of several society-based guidelines (Backhus et al. 2007, Ethics Committee of American Society for Reproductive Medicine (ASRM) 2013, Loren et al. 2013). The American Society of Clinical Oncology (ASCO), ASRM, and American Academy of Pediatrics (AAP) guidelines recommend the discussion of potential fertility impairment at the earliest possible moment after diagnosis, a prompt referral to a qualified specialist if the patient is interested, and the promotion of clinical trials to advance the state of knowledge in fertility preservation. ASRM, AAP, and European Society of Human Reproduction and Embryology (ESHRE) jointly stated: ‘Parents may act to preserve fertility of cancer patients who are minors if the child assents and the intervention is likely to provide net benefits to the child’ (Ethics Committee of American Society for Reproductive Medicine (ASRM) 2013).
Current options for fertility preservation

The current options for men and pubertal boys include sperm banking, and if it is not possible to retrieve a semen sample, testicular sperm extraction, aspiration, or biopsy to obtain testicular tissue for cryopreservation is performed. Prepubertal boys can be consented to a protocol for a testicular biopsy. Work in the field of in vitro male germ cell development using biopsy tissues is ongoing in a number of centers (Orwig & Schlatt 2005, Schlatt et al. 2009, Reuter et al. 2014, Valli et al. 2014). For women 16 years of age or older, the standard of care was to undergo hormone stimulation to obtain mature eggs for fertilization and cryopreservation of embryos prior to starting cancer treatment. Thanks to advances made in oocyte cryopreservation, today, these young women have the additional option of cryopreserving mature oocytes rather than trying to find a sperm donor for fertilization.

Neither of these options is available for women with hormone-sensitive cancers treated with estrogen antagonists including letrozole or for prepubertal girls who are unable to undergo hormone stimulation. For these patients, ovarian tissue cryopreservation is an experimental option, though it is currently reserved for those who have a very high likelihood of losing fertility. The goal is to be able to preserve the immature follicles within the ovarian tissue so that they can be used at a later date to restore reproductive function and fertility. Retransplantation of ovarian tissue that has been cryopreserved through slow freeze protocols or vitrification has led to live births in humans (Dittrich et al. 2015). There remains uncertainty regarding the efficiency of the method, because the total number of transplants that have been performed is unknown, and there is a very real risk that the transplanted tissue can reintroduce cancer cells into the recipient cancer survivor. Ovarian tissue transplantation has also been used to transition prepubertal patients through puberty (Poiriot et al. 2012, Anderson et al. 2013). The fact that surgeons are able to use stored ovarian tissue to replace gonadal function is important and suggests that the tissue that is currently being stored will likely be of future use by patients; however, it is critical that we find ways to reduce the risk of disease transmission.

Advances in ovarian follicle culture

To offer hope of fertility to a greater number of girls and young women with cancer and other diseases in which sterility is the consequence of treatment, we must overcome the challenges of follicle growth and development in vitro. The Oncofertility Consortium has supported fundamental basic research on human ovarian follicle development and fertility, relying on the donations of ovarian tissue for research made to the NPC. This work has led to breakthroughs in our understanding of follicle biology and the effects of cancer treatments (Xu et al. 2011a), as well as new techniques in cryopreservation (Backhus et al. 2007, De Vos et al. 2014) and in vitro follicle growth and maturation (Laronda et al. 2014) that may offer greater options for fertility preservation to the youngest of cancer patients.

The ovarian follicle is a unique structure that contains the oocyte surrounded by and intimately connected to support cells. The normal architecture of the human follicle cannot be maintained in traditional two-dimensional tissue culture dishes. In collaboration with Lonnie Shea, a biomedical engineer, our investigative group developed a three-dimensional culture system that supports follicle development, largely, we believe, by maintaining the links between the gamete and its surrounding cells (Kreeger et al. 2003, Pangas et al. 2003). Using this system, we have shown that the follicle is a fully autonomous unit, able to dictate its activities with very little support from the external environment. When we started our work, we expected that a great deal of manipulation would be required to get the system going. It turns out that the more we did, the less happy our follicles were. We have always known that follicles require follicle-stimulating hormone to stimulate granulosa cell proliferation and hormone production and this turned out to be true in the in vitro setting as well (Kreeger et al. 2005). We also found that the best quality eggs came from oocytes that had been matured in the context of the somatic cells throughout the entire growth phase (Tingen et al. 2011, Tagler et al. 2012, Hornick et al. 2013). Further, the role of the alginate in the follicle culture system is quite simple: to provide a physical support system that maintains the follicle architecture and interaction between the oocyte and the surrounding granulosa and theca cells. What was unclear was whether the physical environment played an active role in the function of the follicle. When we first engineered our follicle culture system, we happened to use very weak gels—serendipitously, we ended up discovering that the more rigid the gel, the less growth of the follicle and the poorer the quality of the resulting egg (West et al. 2007, Woodruff & Shea 2011). So hormones, structure, and environment were the three keys to ovarian follicle maturation, and our current focus is on understanding how to get all three of these contributing factors integrated at the right time and at the right level to produce healthy oocytes in vitro.

Ultimately, it is our hope that in vitro follicle culture technology will be applied clinically to grow immature follicles recovered from cryopreserved ovarian tissue to produce mature oocytes for use in IVF, allowing pediatric patients to 1 day utilize the immature follicles in their stored ovarian tissue to restore future fertility. Thus far, we have grown secondary mouse follicles in alginate that can be matured and fertilized in vitro to produce live offspring (Xu et al. 2006), and we have been able to support primordial, primary, and secondary follicle development from cryopreserved tissue from various animal models (Xu et al. 2009a), nonhuman primates.
Emerging opportunities in oncofertility

(Jin et al. 2010, Hornick et al. 2012, Xu et al. 2013a) and humans (Xu et al. 2009b, Barrett et al. 2010, Laronda et al. 2014). We have also been able to recapitulate the process of ovulation and form a luteal body with cultured mouse follicles, achieving a full ‘menstrual cycle in a dish’ (Skory et al. 2015). We have matured eggs from human follicles (Xiao and T Woodruff unpublished observations) but have not fertilized or activated these eggs because of legal restrictions regarding the use of human gametes for research in the USA (Tingen et al. 2010, Campo-Engelstein et al. 2011, Rodriguez et al. 2011).

Other groups around the globe are also developing three-dimensional follicle culture technologies, and there are similar advances being made in the goat, dog, and baboon (Songsasen et al. 2011, Xu et al. 2011b, Silva et al. 2014). In the monkey, Richard Stouffer et al. have achieved in vitro oocyte maturation, fertilization, and early embryonic development (Xu et al. 2009c, 2010, 2011c, 2013b, Fisher et al. 2013, Rodrigues et al. 2015). The work is progressing, and many labs are continuing to unlock the mechanisms of follicle development, but we do not have a complete system that is ready for use with the tissue stored by young cancer patients. Importantly, advances being made in in vitro follicle growth are not the work of one lab but the concerted effort within the oncofertility field to ensure that the tissue that patients have consented for research protocols is being used to discover and develop new fertility preservation options that will 1 day help other young cancer patients. Patients give their consent with the awareness that we do not yet have the answers needed to provide assurance that their ovarian tissue can be useful outside of the transplant arena, but this is our goal.

Ultimately, it is my hope that 1 day we will not need to rely on preserving ovarian follicles to restore fertility and reproductive function after cancer treatment. As new, smarter therapeutics are created that can treat the disease without causing collateral damage to the ovary and testes, we will no longer have a need for oncofertility. We are learning more and more about the way the female egg and the male sperm respond to toxic drugs. Additionally, new technologies to more precisely target drugs and radiation, as well as biologics that are specific to the disease, are on the horizon. By coupling these technological advancements with a concerted effort to identify the triggers of cancer and refocus our efforts on preventive measures that will either reduce the incidence of disease or diagnose it earlier, we will achieve better outcomes for patients. All of these advances – in cancer prevention, diagnosis, and treatment – will 1 day make it possible to address cancer without affecting future reproductive health, making the word oncofertility and its practice obsolete.

Expanding reproductive education

One of the issues I have been most passionate about is the general understanding of reproductive health terms by the public. The general public and patients have a low comprehension of reproductive science terminology, which creates barriers to discussions about reproductive biology and health and makes health care decision-making difficult. To address this need, I created Repropedia, a website that is curated by members of the global reproductive science community and serves as an authoritative source of definitions for reproductive health terms (http://www.repropedia.org; Smeyers et al. 2012). Importantly, this site can be used to directly interact with any other website by providing pop-up definition boxes. This technology ensures that readers get information in context and do not have to leave their website of interest. This is important for the Oncfertility Consortium’s public-facing blogs and news feeds (https://twitter.com/oncofertility; http://oncofertility.northwestern.edu/news; and https://www.facebook.com/pages/Oncfertility-Consortium/274654090671), ensuring that the definitions of reproductive terms are not stumbling blocks. Repropedia can be linked to any website or blog and, in so doing, improves the comprehension of reproductive terms found anywhere online. In the future, it is my hope that all people will develop a high reproductive science IQ with which they can make fully informed health decisions in a way that improves their individual health and the health of their offspring. The Oncfertility Consortium also focused on education of the next generation of reproductive scientists, clinical researchers, and reproductive health advocates and consumers by engaging high school girls as participants in the Oncfertility Saturday Academy (Faurot & Woodruff 2010). The goal is to use oncofertility as a tool to interest students in the world of research in a fresh new way (http://oncofertility.northwestern.edu/oncofertility-saturday-academies). These programs are provided across the USA (Northwestern University, Chicago, IL; University of California, San Diego; Oregon National Primate Research Center; and University of Pennsylvania), and the girls present their work at the annual Oncfertility Consortium meetings.

Final thoughts

Oncofertility was just an idea 10 years ago. Today it is a distinct field of medicine, offering new hope to cancer patients who will survive their disease, with options for preserving their fertility that prior generations lacked. In the last year alone, 80% of the young cancer patients at my institution received information about fertility as part of their cancer care. I cannot describe just how monumental this shift is for medical practice in North America and perhaps even globally, with reproductive specialists and oncologists working together to improve patient care. For the patients at my institution, the discussions taking place between these two very different disciplines have led to interventions – banking eggs, sperm, embryos, oocytes, or tissue – and
discussions about contraception, with the goal of preserving the patient’s option to have a future family. From the bench to the bedside to babies, oncofertility is now part of the normal lexicon of centers of excellence around the globe, where oncologists and reproductive specialists make fertility after cancer a priority at the time of diagnosis (Woodruff 2013). Shared decision aids and tools for work such as IRB forms provide an altruistic environment in which busy oncologists and reproductive endocrinologists can stay up to date with medical recommendations and have access to the tools they need to implement a program at their institution. The successes in patient care have been paralleled by the efforts of reproductive scientists who are making discoveries in gamete biology that can be rapidly translated to the clinic and by social scientists who are delving into the complex social, ethical, and personal aspects of oncofertility to facilitate decision-making by patients and their caregivers. It is remarkable to think that less than a decade ago, I presented this kind of multidisciplinary, collaborative effort to improve patient care as the future of medicine. For many of our cancer survivors, that future is now, and they are the proud parents of children they thought they might not be able to have. My hope for the future is that we will ultimately eliminate the need for this field through more specific tools that treat the cancer and reduce unwanted side effects of the drugs. Until that time, we will continue to develop the field in a collaborative way that increases the pace of research and its translation into care.

Declaration of interest

The author declares that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review.

Funding

The author receives funding through the following grants: the Center for Reproductive Health after Disease (P50HD076188) from the National Institutes of Health National Center for Translational Research in Reproduction and Infertility (NCTRI), and the National Institutes of Health Roadmap for Medical Research (5UL1DE019587).

Acknowledgements

The author gratefully acknowledges the leaders and members of the Oncofertility Consortium around the world. Specific thanks are due to Kristin Smith who serves as the global oncofertility patient navigator and is tireless in her efforts to provide sound advice to patients, providers, and this author regarding fertility interventions. The author also thanks Brigid Smith and Lauren Ataman who are the current administrative leaders of the Oncofertility Consortium. They are great partners in this work. The author also acknowledges Stacey Tobin, my former student and friend, who provides excellent editorial assistance to me, including for this editorial. I also wish to thank the Society for Reproduction and Fertility and the opportunity to serve as this year’s ‘Sex in Three Cities’ lecturer. It was a real treat meeting so many colleagues and friends across the UK and to interact with the next generation of leaders – your graduate students and fellows. The future of reproductive science and medicine is bright. The concept of a public-facing lecture in reproductive science is an important one and I was thrilled to meet interested laypeople and hope that their enthusiasm translates into support for your work. Finally, I want to acknowledge all of the colleagues who are making a difference in the lives of men and women with a cancer diagnosis. This editorial is necessarily myopic – it would take books to tell the story adequately. Therefore, the citations listed and the statement of progress above represents a tiny fraction of what has been done by leaders around the globe. I apologize for my inadequacy in this regard but am pleased to share a bit of the work done by the Oncofertility Consortium during its formative years.

References


Campo-Engelstein L 2010b For the sake of consistency and fairness: why insurance companies should cover fertility preservation treatment for iatrogenic infertility. Cancer Treatment and Research 156 381–388. (doi:10.1007/mce.2010.038588)

Campo-Engelstein L 2011 Gametes or organs? How should we legally classify ova used for transplantation in the USA? Journal of Medical Ethics 37 166–170. (doi:10.1136/jme.2010.038588)


